BlackRock, Inc. filed Amendment No. 5 to a Schedule 13G with the SEC on October 27, 2026, disclosing its beneficial ownership position in Krystal Biotech Inc. as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: BlackRock reported beneficial ownership of 3,427,645 shares of Krystal Biotech Inc. common stock.
  • Percent of class: The filing states that BlackRock's holdings represent 11.6% of the outstanding class.
  • Sole voting power: BlackRock disclosed sole voting power over 3,358,055 shares.
  • Sole dispositive power: The filing reports sole dispositive power over 3,427,645 shares.
  • Shared voting and dispositive power: Both shared voting power and shared dispositive power are reported as 0.
  • Triggering event date: The date of the event requiring this filing is listed as September 30, 2026.
  • Filer type: BlackRock is identified as a parent holding company (type "HC"), incorporated in Delaware, with its principal office at 50 Hudson Yards, New York, NY 10001.

BlackRock's Amendment No. 5 Ownership Position in Krystal Biotech

According to the filing, BlackRock, Inc. submitted Amendment No. 5 to Schedule 13G to report its beneficial ownership of common stock in Krystal Biotech Inc. (CUSIP 501147102), whose principal executive offices are located at 2100 Wharton Street, Suite 701, Pittsburgh, PA 15203. The event date triggering this amendment is September 30, 2026, and the filing was signed by Spencer Fleming, Managing Director, on October 27, 2026.

The filing discloses that BlackRock beneficially owns 3,427,645 shares, representing 11.6% of the class. Of those shares, BlackRock holds sole voting power over 3,358,055 shares and sole dispositive power over the full 3,427,645 shares. Shared voting and shared dispositive power are each reported as zero. The filing notes that the reported securities reflect holdings of certain business units of BlackRock, Inc. and its subsidiaries and affiliates, consistent with SEC Release No. 34-39538 (January 12, 1998), and do not include securities beneficially owned by other business units whose ownership is disaggregated under that release.

Regarding dividends and disposition proceeds, the filing states that "various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of Krystal Biotech Inc.," and that no single person's interest exceeds five percent of the total outstanding common shares. BlackRock certified in the filing that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

BlackRock, Inc. filed Amendment No. 5 to Schedule 13G reporting beneficial ownership of 3,427,645 shares of Krystal Biotech Inc. common stock, equal to 11.6% of the class, as of September 30, 2026, with sole voting power over 3,358,055 shares.